Education
About Us
Working with TipRanks
Follow Us
Molecular Partners AG (CH:MOLN)
:MOLN
Top Page
Molecular Partners AG
(MOLN)
Select Model
Select Model
Rating:45Neutral
Price Target:
CHF3.50
▲(2.64% Upside)
Action:ReiteratedDate:03/14/26
The score is primarily constrained by weak financial performance (sharp post-2022 revenue decline, heavy losses, and persistent cash burn despite low leverage). Technicals are mixed/neutral with only modest positive momentum, and valuation is not supportive given the negative P/E.
Positive Factors
Innovative Technology Platform
The proprietary DARPins platform allows for the development of targeted therapies, enhancing treatment efficacy and safety, which is a strong competitive advantage in the biotech industry.
Strategic Partnerships
Strategic partnerships with major pharmaceutical firms provide access to additional resources and expertise, which can accelerate the development and commercialization of new therapies.
Pipeline Advancement
The advancement of MP0712 into clinical trials represents progress in the pipeline, potentially leading to new treatment options and revenue streams if successful.
Negative Factors
Declining Revenues
Persistent revenue declines indicate challenges in monetizing the pipeline, which could affect long-term financial sustainability and operational funding.
Cash Flow Issues
Negative cash flow reflects ongoing cash burn, which can strain resources and necessitate additional financing, impacting long-term operational stability.
Profitability Concerns
Sustained losses and negative margins highlight profitability challenges, which could hinder the company's ability to reinvest in R&D and growth initiatives.
Molecular Partners AG (MOLN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF134.04M
Dividend YieldN/A
Average Volume (3M)17.77K
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue Growth-100.00%
EPS Growth14.45%
CountryCH
Employees158
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.34
Shares Outstanding40,374,640
10 Day Avg. Volume21,556
30 Day Avg. Volume17,775
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-2.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF15.00Price Target Upside339.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.22
Revenue Forecast (FY)CHF5.46M
Molecular Partners AG Business Overview & Revenue Model
Company DescriptionMolecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
How the Company Makes MoneyMolecular Partners generates revenue primarily through a combination of licensing agreements, collaborations with pharmaceutical companies, and potential milestone payments associated with the development of its therapeutic candidates. The company often enters into partnerships that allow it to co-develop drugs, which can provide upfront payments and royalties on future sales. Additionally, if its drug candidates receive regulatory approval, the company can earn significant milestone payments from partners. The monetization of its DARPins technology through these collaborations is a critical aspect of its revenue model, alongside potential future product sales.
Molecular Partners AG Earnings Call Summary
Earnings Call Date:Mar 06, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Aug 31, 2026
Earnings Call Sentiment Positive
Molecular Partners demonstrated significant progress in advancing their pipeline, particularly with the radio DARPin franchise and T cell engager 533, while maintaining a strong financial position. However, the discontinuation of the Novartis collaboration and resulting revenue impact were notable drawbacks.Q4-2024 Updates
Positive Updates
Successful Execution of 2024 Program Goals
Molecular Partners advanced their radio DARPin franchise with the lead compound DLL3 targeting 712 passing all IND-enabling studies, ready for clinical trials. They selected mesothelin as a new target and expanded their collaboration with Orano Med, securing 10 slots for Lead-212 isotope.
Positive Financial Health
The company ended 2024 with a cash balance of CHF 149 million, which supports operations into 2027. They raised CHF 20 million through financing, maintaining a solid financial base with no debt.
Encouraging Clinical Results and Pipeline Progression
The T cell engager 533 showed significant improvements in efficacy with new dosing strategies, resulting in 3 complete responses out of 8 patients treated past day 12.
Negative Updates
Novartis Collaboration Setback
The collaboration with Novartis was not continued as the targets did not progress as expected. This decision was mutual and based on strategic interests.
Revenue Decline from Novartis Collaboration
Revenue decreased as 2024 recognized the last part of the upfront payment from the Novartis collaboration, with no further revenue expected from this source.
Company Guidance
During the Molecular Partners Fourth Quarter and Full Year 2024 Results Call, several notable metrics and guidance were provided. For the fiscal year 2024, the company reported revenues of CHF 5 million, exclusively from the Novartis collaboration. Operating expenses were CHF 66 million, within the guidance range of CHF 65 million to CHF 70 million, with 74% allocated to R&D. The net financial result benefited from high interest rates, contributing to an end-of-year cash balance of CHF 149 million, down from CHF 187 million the previous year, resulting in a cash burn of CHF 54 million. Looking ahead to 2025, Molecular Partners anticipates operating expenses between CHF 55 million and CHF 65 million, excluding potential partnership payments. The company is focused on advancing its radio DARPin programs, particularly MP0712, with expectations to start clinical trials and provide initial imaging data by the end of the year, while also progressing with its T cell engager program, MP0533, in AML, with new dosing amendments and outcomes expected by year-end.Molecular Partners AG Financial Statement Overview
Summary
Overall fundamentals are weak: revenue collapsed after 2022 and the company returned to heavy losses with negative margins, alongside sustained negative operating/free cash flow in 2023–2025. The main offset is low leverage, but equity has shrunk materially, reflecting ongoing burn.Income Statement
Profitability is weak and volatile. After a one-off strong year in 2022 (high revenue and solid profits), the company reverted to heavy losses in 2023–2025 with negative gross profit and deeply negative margins where provided. Revenue has also contracted sharply from 2022 levels, falling to very low/near-zero levels by 2025, highlighting a business model that is currently not generating sustainable commercial income.18
Very Negative
Balance Sheet
Leverage is low, with debt-to-equity consistently very modest (roughly ~0.02 in 2022–2024), which reduces solvency risk. However, the equity base has been shrinking materially (from 235.2M in 2022 to 80.3M in 2025), consistent with sustained losses and cash burn. Returns on equity are negative in loss years, underscoring that the balance sheet is being consumed rather than compounded.62
Positive
Cash Flow
Cash generation has deteriorated meaningfully. Operating cash flow and free cash flow are strongly negative in 2023–2025 (about -50M to -60M per year), reversing the strong positive cash flow in 2022. While free cash flow has broadly tracked net income directionally (loss-making years show negative cash flow), the persistence of sizable outflows increases funding risk if conditions don’t improve.24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 4.97M | 7.04M | 189.56M | 9.33M |
| Gross Profit | -2.15M | -42.53M | -40.81M | 138.81M | -46.39M |
| EBITDA | -53.26M | -51.63M | -59.52M | 119.00M | -60.66M |
| Net Income | -61.65M | -54.04M | -61.98M | 117.85M | -63.78M |
Balance Sheet | |||||
| Total Assets | 102.11M | 158.53M | 198.35M | 262.26M | 172.67M |
| Cash, Cash Equivalents and Short-Term Investments | 93.06M | 149.44M | 186.89M | 249.14M | 132.81M |
| Total Debt | 3.64M | 2.44M | 3.65M | 4.85M | 6.04M |
| Total Liabilities | 21.77M | 16.89M | 21.92M | 27.09M | 65.38M |
| Stockholders Equity | 80.33M | 141.64M | 176.43M | 235.17M | 107.29M |
Cash Flow | |||||
| Free Cash Flow | -50.24M | -59.97M | -59.81M | 117.15M | -92.26M |
| Operating Cash Flow | -49.53M | -59.25M | -59.01M | 118.57M | -90.95M |
| Investing Cash Flow | 70.82M | 40.49M | 44.64M | -101.12M | -22.24M |
| Financing Cash Flow | -1.15M | 14.43M | -1.17M | -1.57M | 50.58M |
Molecular Partners AG Technical Analysis
Negative
3.41
Price Trends
3.51
Negative
3.37
Negative
3.17
Positive
Market Momentum
0.04
Positive
38.75
Neutral
40.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MOLN, the sentiment is Negative. The current price of 3.41 is below the 20-day moving average (MA) of 3.77, below the 50-day MA of 3.51, and above the 200-day MA of 3.17, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 38.75 is Neutral, neither overbought nor oversold. The STOCH value of 40.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:MOLN.
Molecular Partners AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | CHF339.62M | -487.07 | ― | ― | 744.64% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | CHF204.05M | -0.98 | -301.13% | ― | -56.85% | -186.55% | |
45 Neutral | CHF134.04M | -2.05 | -51.05% | ― | -100.00% | 14.45% | |
45 Neutral | CHF736.64M | -8.17 | ― | ― | 229.23% | 63.47% |
* Healthcare Sector Average
CH:MOLN
Molecular Partners AG
3.32
-0.18
-5.14%
CH:IDIA
Idorsia Ltd
3.40
2.22
188.14%
CH:NWRN
Newron Pharmaceuticals SpA
16.36
7.76
90.23%
CH:SANN
Santhera Pharmaceuticals Holding
14.54
-0.26
-1.76%
CH:XLS
Xlife Sciences Ltd.
23.00
3.10
15.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.